IRIS Accounts Production v25.1.4.42 10612687 Board of Directors 1.1.24 31.12.24 31.12.24 false true false false true false Ordinary B 0.01000 Ordinary A1 0.01000 Ordinary A2 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh106126872023-12-31106126872024-12-31106126872024-01-012024-12-31106126872022-12-31106126872023-01-012023-12-31106126872023-12-3110612687ns15:EnglandWales2024-01-012024-12-3110612687ns14:PoundSterling2024-01-012024-12-3110612687ns10:Director12024-01-012024-12-3110612687ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3110612687ns10:SmallEntities2024-01-012024-12-3110612687ns10:AuditExemptWithAccountantsReport2024-01-012024-12-3110612687ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3110612687ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3110612687ns10:FullAccounts2024-01-012024-12-3110612687ns10:OrdinaryShareClass12024-01-012024-12-3110612687ns10:OrdinaryShareClass22024-01-012024-12-3110612687ns10:OrdinaryShareClass32024-01-012024-12-3110612687ns10:Director22024-01-012024-12-3110612687ns10:Director32024-01-012024-12-3110612687ns10:Director42024-01-012024-12-3110612687ns10:Director52024-01-012024-12-3110612687ns10:Director62024-01-012024-12-3110612687ns10:RegisteredOffice2024-01-012024-12-3110612687ns5:CurrentFinancialInstruments2024-12-3110612687ns5:CurrentFinancialInstruments2023-12-3110612687ns5:ShareCapital2024-12-3110612687ns5:ShareCapital2023-12-3110612687ns5:SharePremium2024-12-3110612687ns5:SharePremium2023-12-3110612687ns5:FurtherSpecificReserve1ComponentTotalEquity2024-12-3110612687ns5:FurtherSpecificReserve1ComponentTotalEquity2023-12-3110612687ns5:RetainedEarningsAccumulatedLosses2024-12-3110612687ns5:RetainedEarningsAccumulatedLosses2023-12-3110612687ns5:ComputerEquipment2024-01-012024-12-3110612687ns5:ComputerEquipment2023-12-3110612687ns5:ComputerEquipment2024-12-3110612687ns5:ComputerEquipment2023-12-3110612687ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3110612687ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3110612687ns10:OrdinaryShareClass12024-12-3110612687ns10:OrdinaryShareClass22024-12-3110612687ns10:OrdinaryShareClass32024-12-3110612687ns5:RetainedEarningsAccumulatedLosses2023-12-3110612687ns5:SharePremium2023-12-3110612687ns5:FurtherSpecificReserve1ComponentTotalEquity2023-12-3110612687ns5:RetainedEarningsAccumulatedLosses2024-01-012024-12-31
REGISTERED NUMBER: 10612687 (England and Wales)










Unaudited Financial Statements

for the Year Ended 31 December 2024

for

Ridge Pharma Limited

Ridge Pharma Limited (Registered number: 10612687)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Report of the Accountants 2

Balance Sheet 3

Notes to the Financial Statements 5


Ridge Pharma Limited

Company Information
for the Year Ended 31 December 2024







DIRECTORS: Mr Brendon Dominic Mcdonagh
Mr Jonathan Andrew Hurford
Mr Harry Thomas Stratford
Mr Brian Alexander Mcewan
Mr Martijn Christian Kleibergen
Ms Tasmin Lizabeth Morgan





REGISTERED OFFICE: 12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL





REGISTERED NUMBER: 10612687 (England and Wales)





ACCOUNTANTS: Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL

Ridge Pharma Limited

Report of the Accountants to the Directors of
Ridge Pharma Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 31 December 2024 set out on page nil and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Avalon Accounting Limited
12 Park Lane
Tilehurst
Reading
Berkshire
RG31 5DL


Date: .............................................

Ridge Pharma Limited (Registered number: 10612687)

Balance Sheet
31 December 2024

2024 2023
Notes £    £   
Fixed assets
Tangible assets 4 17,379 14,238

Current assets
Stocks 5 1,408,491 887,746
Debtors 6 657,749 716,849
Prepayments and accrued income 66,181 46,091
Cash at bank and in hand 477,530 534,917
2,609,951 2,185,603
Creditors
Amounts falling due within one year 7 (2,103,698 ) (1,611,311 )
Net current assets 506,253 574,292
Total assets less current liabilities 523,632 588,530

Non-current assets 141,871 113,130
Net assets 665,503 701,660

Capital and reserves
Called up share capital 9 2,196 2,196
Share premium 10 4,693,388 4,693,388
Fund raising cost 10 (294,127 ) (294,127 )
Retained earnings 10 (3,735,954 ) (3,699,797 )
Shareholders' funds 665,503 701,660

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Ridge Pharma Limited (Registered number: 10612687)

Balance Sheet - continued
31 December 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 July 2025 and were signed on its behalf by:





Mr Jonathan Andrew Hurford - Director


Ridge Pharma Limited (Registered number: 10612687)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

Ridge Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

TURNOVER
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

TANGIBLE FIXED ASSETS
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Computer equipment - 25% on reducing balance

STOCKS
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

TAXATION
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

DEFERRED TAX
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

PENSION COSTS AND OTHER POST-RETIREMENT BENEFITS
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 22 (2023 - 22 ) .

Ridge Pharma Limited (Registered number: 10612687)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 January 2024 31,146
Additions 8,284
At 31 December 2024 39,430
DEPRECIATION
At 1 January 2024 16,908
Charge for year 5,143
At 31 December 2024 22,051
NET BOOK VALUE
At 31 December 2024 17,379
At 31 December 2023 14,238

5. STOCKS
2024 2023
£    £   
Closing stock 1,408,491 837,378
Stock in Transit - 50,368
1,408,491 887,746

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 654,122 713,222
Deposits with tenure less than
12 months 3,627 3,627
657,749 716,849

Ridge Pharma Limited (Registered number: 10612687)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Bank loans and overdrafts (see note 8) 350,630 -
Other loans (see note 8) 749,999 749,999
Trade creditors 475,736 398,985
Deferred Tax B/S 3,302 2,556
Social security 53,458 106,561
VAT 273,356 258,469
Other creditors 4,097 3,801
Accrued expense 49,286 22,106
Accrued Interest on
Convertible Loan 2023 143,834 68,834
2,103,698 1,611,311

8. LOANS

An analysis of the maturity of loans is given below:

2024 2023
£    £   
Amounts falling due within one year or on demand:
Abcor Working Capital Loan 350,630 -
Loan against Stocks 749,999 749,999
1,100,629 749,999

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
125,437 Ordinary B £0.01 1,254 1,254
84,792 Ordinary A1 £0.01 848 848
9,422 Ordinary A2 £0.01 94 94
2,196 2,196

10. RESERVES
Fund
Retained Share raising
earnings premium cost Totals
£    £    £    £   

At 1 January 2024 (3,699,797 ) 4,693,388 (294,127 ) 699,464
Deficit for the year (36,157 ) (36,157 )
At 31 December 2024 (3,735,954 ) 4,693,388 (294,127 ) 663,307